Biotech Values

[DewDiligence]

Re: Addressable market for substitutable FoB’s

I do not agree with your implicit assumption in #msg-69361018 that the addressable market for substitutable FoB’s is merely what is left over after non-substitutable FoB’s are deducted from the total market for off-patent biologics. Rather, substitutable FoB’s also have an opportunity to claim a portion of the addressable market for non-substitutable FoB’s (which I estimated at 35-40% of the pie in #msg-69358423).

Proviso: To take advantage of the above, development programs for substitutable FoB have to be started early—i.e. they have to be well into the research phase even now.